Remus Pharmaceuticals reported a consolidated profit after tax of INR 17.50 crores for H1 FY26, a growth of 33.97% compared to H1 FY25, alongside a revenue increase of 46.80%. The announcement was made in a press release on November 10, 2025, detailing their financial results and business highlights including new market entries and successful product awards.